LABELS · 58b287d1-24f5-4dfe-84ca-898a8a5b9302

Thalomid

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2023-03-24
Captured: 2026-09-09T23:37:47.659725+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM See full prescribing information for complete boxed warning. EMBRYO -FETAL TOXICITY • If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could be pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. • Pregnancy must be excluded before start of treatment. Prevent pregnancy thereafter by the use of two reliable methods of contraception. ( 5.1 , 8.3 ) THALOMID is only available through a restricted distribution program, the THALOMID REMS ® program ( 5.2 ). VENOUS THROMBOEMBOLISM • Significant increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma receiving THALOMID with dexamethasone ( 5.3 ). EMBRYO-FETAL TOXICITY If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could become pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. Because of this toxicity and in an effort to make the chance of embryo-fetal exposure to THALOMID as negligible as possible, THALOMID is approved for marketing only through a special restricted distribution program: THALOMID REMS program, approved by the Food and Drug Administration. Information about THALOMID and the THALOMID REMS program is available at www.thalomidrems.com or by calling the REMS Call Center at 1-888-423-5436. VENOUS THROMBOEMBOLISM The use of THALOMID in multiple myeloma results in an increased risk of venous thromboembolism, such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when THALOMID is used in combination with standard chemotherapeutic agents including dexamethasone. In one controlled trial, the rate of venous thromboembolism was 22.5% in patients receiving THALOMID in combination with dexamethasone compared to 4.9% in patients receiving dexamethasone alone (p = 0.002). Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Instruct patients to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Consider thromboprophylaxis based on an assessment of individual patients' underlying risk factors.

Indications and usage: exact source text

1 INDICATIONS AND USAGE • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2) ].

Full extracted label fields

application numbers

NDA020785

boxed warning exact

WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM See full prescribing information for complete boxed warning. EMBRYO -FETAL TOXICITY • If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could be pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. • Pregnancy must be excluded before start of treatment. Prevent pregnancy thereafter by the use of two reliable methods of contraception. ( 5.1 , 8.3 ) THALOMID is only available through a restricted distribution program, the THALOMID REMS ® program ( 5.2 ). VENOUS THROMBOEMBOLISM • Significant increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma receiving THALOMID with dexamethasone ( 5.3 ). EMBRYO-FETAL TOXICITY If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could become pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. Because of this toxicity and in an effort to make the chance of embryo-fetal exposure to THALOMID as negligible as possible, THALOMID is approved for marketing only through a special restricted distribution program: THALOMID REMS program, approved by the Food and Drug Administration. Information about THALOMID and the THALOMID REMS program is available at www.thalomidrems.com or by calling the REMS Call Center at 1-888-423-5436. VENOUS THROMBOEMBOLISM The use of THALOMID in multiple myeloma results in an increased risk of venous thromboembolism, such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when THALOMID is used in combination with standard chemotherapeutic agents including dexamethasone. In one controlled trial, the rate of venous thromboembolism was 22.5% in patients receiving THALOMID in combination with dexamethasone compared to 4.9% in patients receiving dexamethasone alone (p = 0.002). Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Instruct patients to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Consider thromboprophylaxis based on an assessment of individual patients' underlying risk factors.

brand names

Thalomid

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061

generic names

THALIDOMIDE

58b287d1-24f5-4dfe-84ca-898a8a5b9302

indications and usage exact

1 INDICATIONS AND USAGE • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2) ].

indications and usage tables exact

is original packager

true

manufacturer names

Celgene Corporation

matched search terms

myeloma

package ndcs

59572-205-14
59572-205-94
59572-205-17
59572-205-97
59572-210-15
59572-210-95
59572-215-13
59572-215-93
59572-220-16
59572-220-96

product ndcs

59572-205
59572-210
59572-215
59572-220

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

200390
213360
360176
360177
404449
404450
700416
700418

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00300.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · unclassified context

application numbers

NDA020785

brand names

Thalomid

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 223
end exclusive: true
exact text: 1 INDICATIONS AND USAGE • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cuta
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 0

current approval status

not_reconciled

duplicate text group

dup-9cfcc7cc8089ff93fe5a

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-ba1c63a19dfa9534af5a

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 23
end exclusive: true
exact text: 1 INDICATIONS AND USAGE
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 2 · positive indication candidate

application numbers

NDA020785

brand names

Thalomid

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 355
end exclusive: true
exact text: 1 INDICATIONS AND USAGE • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL tr
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 0

current approval status

not_reconciled

duplicate text group

dup-0589199467bda93b0886

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-70fffef0a8a91a121a32

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

end: 81
end exclusive: true
exact text: is indicated
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 69

qualifier mentions

context exact
• THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).
kind
regimen
polarity
not_inferred
span
end
154
end exclusive
true
exact text
in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
35

regulatory links

candidate source span
end
155
end exclusive
true
exact text
• THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
24
fda indication exact
Newly diagnosed multiple myeloma
fda source row index
100
fda source sha256
91f921503728c2afb0ec500d9c6034553e0b81d5af260a20c5478686c1127a7e
fda status record id
fda-aa-5b7c1b230a7c2c331a79
interpretation
Source wording correspondence to a dated FDA status row; current approval not certified
match method
whole_indication_literal_normalized_substring
matching review status
source_comparison_only_clinical_review_pending
scope relationship
whole_fda_indication_text_present
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
status category
verified_clinical_benefit
status event date
2014-06-19
supporting anchor spans

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 155
end exclusive: true
exact text: • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 24

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Read indication-specific status → · whole_fda_indication_text_present

Passage 3 · unclassified context

application numbers

NDA020785

brand names

Thalomid

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 363
end exclusive: true
exact text: 1 INDICATIONS AND USAGE • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 0

current approval status

not_reconciled

duplicate text group

dup-ed4c5459106e5f89c3c7

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-99747679dab5bad098e9

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 163
end exclusive: true
exact text: ( 1.1 )
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 156

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA020785

brand names

Thalomid

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 498
end exclusive: true
exact text: 1 INDICATIONS AND USAGE • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 0

current approval status

not_reconciled

duplicate text group

dup-849ecea79e0b4a0e43e2

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-ce7e878c0c703d8c1e45

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

end: 187
end exclusive: true
exact text: is indicated
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 175

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 298
end exclusive: true
exact text: • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 164

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · limitation of use

application numbers

NDA020785

brand names

Thalomid

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 610
end exclusive: true
exact text: of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexametha
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 99

current approval status

not_reconciled

duplicate text group

dup-8d1b33fe0e469ad42f9c

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-c81b076637aceb0e2800

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

Source null

qualifier mentions

context exact
THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.
kind
regimen
polarity
not_inferred
span
end
409
end exclusive
true
exact text
as monotherapy for such ENL treatment in the presence of moderate to severe neuritis
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
325

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 410
end exclusive: true
exact text: THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 299

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · positive indication candidate

application numbers

NDA020785

brand names

Thalomid

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 742
end exclusive: true
exact text: of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Eryt
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 211

current approval status

not_reconciled

duplicate text group

dup-edf13916b7a9996d5af5

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-199999f5548870e64c0e

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

end: 437
end exclusive: true
exact text: is also indicated
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 420

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 542
end exclusive: true
exact text: THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 411

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

NDA020785

brand names

Thalomid

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 750
end exclusive: true
exact text: such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nod
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 343

current approval status

not_reconciled

duplicate text group

dup-15f77f2ec9573d45532a

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-6b7beaf53c94d2cbbe91

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 550
end exclusive: true
exact text: ( 1.2 )
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 543

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA020785

brand names

Thalomid

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 933
end exclusive: true
exact text: L treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monothe
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 351

current approval status

not_reconciled

duplicate text group

dup-54457fae13dc1e103dd5

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-1d8cf78ba4bdf4f44db2

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

end: 627
end exclusive: true
exact text: is indicated
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 615

qualifier mentions

context exact
1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] .
kind
regimen
polarity
not_inferred
span
end
726
end exclusive
true
exact text
in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
581

regulatory links

candidate source span
end
733
end exclusive
true
exact text
1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] .
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
551
fda indication exact
Newly diagnosed multiple myeloma
fda source row index
100
fda source sha256
91f921503728c2afb0ec500d9c6034553e0b81d5af260a20c5478686c1127a7e
fda status record id
fda-aa-5b7c1b230a7c2c331a79
interpretation
Source wording correspondence to a dated FDA status row; current approval not certified
match method
whole_indication_literal_normalized_substring
matching review status
source_comparison_only_clinical_review_pending
scope relationship
whole_fda_indication_text_present
source url
https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
status category
verified_clinical_benefit
status event date
2014-06-19
supporting anchor spans

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 733
end exclusive: true
exact text: 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] .
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 551

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Read indication-specific status → · whole_fda_indication_text_present

Passage 9 · positive indication candidate

application numbers

NDA020785

brand names

Thalomid

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1096
end exclusive: true
exact text: urrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 534

current approval status

not_reconciled

duplicate text group

dup-cd73cb646704826712ad

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-1fb049d636dcd9c36313

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

end: 785
end exclusive: true
exact text: is indicated
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 773

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 896
end exclusive: true
exact text: 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 734

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · limitation of use

application numbers

NDA020785

brand names

Thalomid

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1171
end exclusive: true
exact text: MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2) ].
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 697

current approval status

not_reconciled

duplicate text group

dup-8d1b33fe0e469ad42f9c

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-154fad3578eaa6286e3c

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

Source null

qualifier mentions

context exact
THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.
kind
regimen
polarity
not_inferred
span
end
1007
end exclusive
true
exact text
as monotherapy for such ENL treatment in the presence of moderate to severe neuritis
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
923

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 1008
end exclusive: true
exact text: THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 897

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

NDA020785

brand names

Thalomid

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1171
end exclusive: true
exact text: of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2) ].
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 809

current approval status

not_reconciled

duplicate text group

dup-940ab69e691409bca0d7

extraction review status

automated_candidate_pending_source_review

generic names

THALIDOMIDE

ind-span-90ec8dd0188030902a6a

label id

58b287d1-24f5-4dfe-84ca-898a8a5b9302

positive predicate support span

end: 1035
end exclusive: true
exact text: is also indicated
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 1018

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
154
end exclusive
true
exact text
multiple myeloma (MM)
label id
58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start
133

source span

end: 1171
end exclusive: true
exact text: THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2) ].
label id: 58b287d1-24f5-4dfe-84ca-898a8a5b9302
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 93b016fd71af9436d6661449aa1aacb367a91c42109a40a69fbd8024c0451d5c
start: 1009

source url

https://api.fda.gov/drug/label.json?search=id%3A%2258b287d1-24f5-4dfe-84ca-898a8a5b9302%22

spl effective date

2023-03-24

spl set id

2eda833b-1357-4ed4-a093-194524fcb061

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice